ABSI News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

AB

Mkt Cap

$1.41B

Volume

2.93M

Next Earnings

November 11th

Loading chart

AB

ABSIAbsci Corporation Common Stock

ABSI

Pay with—

Available Balance0.00

AB

Mkt Cap

$1.52B

Volume

2.93M

Next Earnings

November 11th

Chart Financials Earnings News About Insider Filings

Global Drug Discovery AI Tools Market - Strategic Forecast 2026-2032 | Generative AI, Cloud Platforms, and Integrated R&D Workflows Create New Growth OpportunitiesA comprehensive market research report examines the growing role of AI tools in drug discovery, covering applications in target identification, molecular design, and preclinical testing. The market is shifting from isolated computational experiments toward integrated workflows combining data systems and laboratory validation. Success depends on data quality, model interpretability, regulatory compliance, and multidisciplinary expertise across biology, chemistry, and data science.GlobeNewswire Inc. · Oct 5, 2026

AI Poised to Reshape Blood Cancer Therapeutics as Investment Surges Past $2 Billion Across Leading Biotech and Pharma PlayersArtificial intelligence is transforming blood cancer drug discovery and development, with over $2 billion in investment from major biotech and pharma companies. AI is reducing clinical trial timelines by up to 50%, improving patient selection, and enabling next-generation therapies like CAR-T and antibody-drug conjugates. North America leads with 40% of global market share, while Asia-Pacific emerges as a significant growth region.GlobeNewswire Inc. · Aug 25, 2026

The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath ItThe AI drug discovery field is shifting focus from building the most powerful models to establishing trustworthy, connected biological data foundations. MindWalk Holdings (HYFT) has positioned itself as a leader in this 'context layer' approach with its ReefIQ and LensAI platforms, reporting 52% YoY revenue growth and its first recurring platform contract. The article examines how this represents a maturation of the sector beyond initial hype, comparing MindWalk's strategy to peers like Absci, Recursion, Schrödinger, and Certara.Benzinga · Jun 16, 2026

AMD Reveals A $6.5 Million Marvell Bet That's Already SoaringAMD disclosed a $6.5 million stake in Marvell Technology through its latest 13F filing, with the position showing an estimated unrealized gain of approximately $4.3 million as Marvell shares have risen about 66% from AMD's implied entry price. The investment reflects AMD's exposure to AI infrastructure and data center semiconductor opportunities. AMD also holds positions in Absci Corp, Sanmina Corp, and Xanadu Quantum Technologies.Benzinga · May 13, 2026

Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Absci Corporation granted 276,200 non-statutory stock options to a newly-hired non-executive employee on May 1, 2026, as an inducement for employment. The options have an exercise price of $4.92 per share with a 10-year term and vest over four years, with 25% vesting after one year and the remaining 75% vesting in equal monthly installments over the following three years.GlobeNewswire Inc. · May 5, 2026

Absci Strengthens Clinical Leadership with Appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical OfficerAbsci Corporation announced the appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer to lead clinical development of its AI-designed therapeutics pipeline. Dr. Somaratne joins from Vertex Pharmaceuticals with extensive experience in clinical development. Chief Innovation Officer Andreas Busch will retire on March 31, 2026 and transition to co-chair the Scientific Advisory Board.GlobeNewswire Inc. · Mar 3, 2026

Absci to Report Business Updates and Third Quarter 2025 Financial and Operating Results on November 12, 2025Absci, a clinical-stage biotech company using generative AI for drug discovery, will report its Q3 2025 financial and operating results on November 12, 2025, via a webcast conference call.Benzinga · Oct 29, 2025

Absci to Participate in Upcoming Investor ConferencesAbsci Corporation announced participation in upcoming healthcare investor conferences and plans to host a key opinion leader (KOL) seminar on its ABS-201 hair regrowth program, with an accelerated Phase 1/2a trial expected to begin in December 2025.GlobeNewswire Inc. · Oct 27, 2025

Absci Stock Offers High-Risk AI Biotech Exposure With 110% Upside ForecastAbsci Corp, a small AI biotech company, offers high-risk investment potential in drug discovery using generative AI, with multiple drug candidates in clinical trials and strategic partnerships with major pharma companies.Investing.com · Oct 14, 2025

Computer-Aided Drug Design (CADD) Market Competitive Landscape Report – Towards HealthcareThe global CADD market is experiencing rapid growth, projected to generate substantial revenue between 2025-2034, driven by technological innovations, AI integration, and increasing demand across pharmaceutical and research sectors.GlobeNewswire Inc. · Oct 9, 2025

to start trading

AB

ABSIAbsci Corporation Common Stock

ABSI

Pay with—

Available Balance0.00

Your PositionYou don't own any ABSI yet.

Related Tickers

Earnings